IL-33 Promotes Gastric Cancer Cell Invasion and Migration Via ST2-ERK1/2 Pathway

Yu, Xi-Xiang; Hu, Zhe; Shen, Xian; Dong, Li-Yang; Zhou, Wei-Zhong; Hu, Wen-Hao
May 2015
Digestive Diseases & Sciences;May2015, Vol. 60 Issue 5, p1265
Academic Journal
Background: As a pro-inflammatory cytokine, IL-33 has been demonstrated to play an important role in tumor progression. It is reported that IL-33 is highly expressed in the serum and tumor tissues of patients with gastric cancer. However, the function of IL-33 in gastric cancer remains elusive. We here tried to elucidate the effects of IL-33 on gastric cancer cell invasion and migration. Methods: Invasion assay and migration assay were performed to assess the effects of IL-33 on gastric cancer cell invasion and migration. ST2 receptor was silenced by siRNA, and ERK1/2 pathway was inhibited by U0126. Protein levels of MMP-3 and IL-6 in cell supernatant were measured by ELISA. Results: IL-33 promoted the invasion and migration of gastric cancer cells, in a dose-dependent manner. Knockdown of the IL-33 receptor ST2 attenuated the IL-33-mediated invasion and migration. Furthermore, via ST2 receptor, IL-33 induced the activation of ERK1/2 and increased the secretion of MMP-3 and IL-6. In addition, blockage of ERK1/2 pathway resulted in inhibition of invasion and migration induced by IL-33, and downregulation of MMP-3 and IL-6 production. Conclusions: IL-33 promotes gastric cancer cell invasion and migration by stimulating the secretion of MMP-3 and IL-6 via ST2-ERK1/2 pathway. Thus, IL-33 may be a useful marker for the diagnosis and treatment of gastric cancer.


Related Articles

  • GASTRIC CANCER TUMOR MARKERS. Gireada, Alexandra; Balescu, Irina; Bacalbasa, Nicolae // Romanian Medical Journal;2015, Vol. 62 Issue 4, p403 

    Gastric cancer remains an aggressive malignancy responsible for a high number of deaths annually. An important method used in order to determine the response to treatment, follow-up and detection of recurrence in association with imagistic examinations remains laboratory determination of tumor...

  • No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy. Bernards, N.; Creemers, G. J.; Nieuwenhuijzen, G. A. P.; Bosscha, K.; Pruijt, J. F. M.; Lemmens, V. E. P. P. // Annals of Oncology;Dec2013, Vol. 24 Issue 12, p3056 

    Background Gastric cancer often presents in a metastasized stage. We conducted a population-based study to evaluate trends in systemic treatment and survival of metastatic noncardia gastric cancer. Patients and methods All patients with noncardia adenocarcinoma of the stomach, diagnosed between...

  • Estimation of an Optimal Chemotherapy Utilisation Rate for Upper Gastrointestinal Cancers: Setting an Evidence-Based Benchmark for the Best-Quality Cancer Care. Ng, Weng; Jacob, Susannah; Delaney, Geoff; Do, Viet; Barton, Michael // Gastroenterology Research & Practice;3/26/2015, Vol. 2015, p1 

    Aims. The proportion of patients with upper gastrointestinal cancers that received chemotherapy varies widely in Australia and internationally, indicating a need for a benchmark rate of chemotherapy utilisation. We developed evidence-based models for upper gastrointestinal cancers to estimate...

  • Diversity of Clinical Implication of B-Cell Translocation Gene 1 Expression by Histopathologic and Anatomic Subtypes of Gastric Cancer. Kanda, Mitsuro; Oya, Hisaharu; Nomoto, Shuji; Takami, Hideki; Shimizu, Dai; Hashimoto, Ryoji; Sueoka, Satoshi; Kobayashi, Daisuke; Tanaka, Chie; Yamada, Suguru; Fujii, Tsutomu; Nakayama, Goro; Sugimoto, Hiroyuki; Koike, Masahiko; Fujiwara, Michitaka; Kodera, Yasuhiro // Digestive Diseases & Sciences;May2015, Vol. 60 Issue 5, p1256 

    Background: Genetic signatures may differ by histopathologic and anatomic subtypes of gastric cancer (GC). B-cell translocation gene 1 ( BTG1) was identified as one of genes downregulated in GC tissues from our microarray data. Aims: To evaluate the clinical implications of BTG1 expression in GC...

  • A tumor marker panel scoring system to improve clinical stage in gastric cancer. Jun Gong; Jiu-Yang Liu; Chun-Wei Peng; Yang Yu; Xiao-Hua Leng; Cong-Hua Xie; Yan Li // International Journal of Clinical & Experimental Medicine;2016, Vol. 9 Issue 7, p14304 

    Objective: To investigate the correlation among tumor markers test/reference cutoff ratio score (TRRS), disease progression and clinical stages in gastric cancer (GC). Methods: 708 patients hospitalized because of GC for the first time with preoperative tumor makers [carcinoembryonic antigen...

  • Prognostic Model Based on Systemic Inflammatory Response and Clinicopathological Factors to Predict Outcome of Patients with Node-Negative Gastric Cancer. Qu, Jing-lei; Qu, Xiu-juan; Li, Zhi; Zhang, Jing-dong; Liu, Jing; Teng, Yue-e; Jin, Bo; Zhao, Ming-fang; Yu, Ping; Shi, Jing; Fu, Ling-yu; Wang, Zhen-ning; Liu, Yun-peng // PLoS ONE;Jun2015, Vol. 10 Issue 6, p1 

    Prognostic models are generally used to predict gastric cancer outcomes. However, no model combining patient-, tumor- and host-related factors has been established to predict outcomes after radical gastrectomy, especially outcomes of patients without nodal involvement. The aim of this study was...

  • P-0146 TO SELECT THE THERAPIES IN GASTRIC CARCINOID TUMORS. Sei, Kurokawa // Annals of Oncology;Jun2014, Vol. 25 Issue suppl_2, pii58 

    No abstract available.

  • Fas Signaling Promotes Gastric Cancer Metastasis through STAT3-Dependent Upregulation of Fascin. Yang, Yunshan; Zhao, Qiyu; Cai, Zhijian; Cheng, Guoping; Chen, Ming; Wang, Jiaoli; Zhong, Haijun // PLoS ONE;May2015, Vol. 10 Issue 5, p1 

    Background: Fas signaling-activated signal transducers and activators of transcription 3 (STAT3) is required for Fascin upregulation. As an actin-bundling protein, Fascin can mediate gastric cancer (GC) cell migration. Methods: Gastric cancer AGS cells were treated with anti-Fas (5 μg/ml)...

  • Metachronous Double Primary Cancer after Diagnosis of Gastric Cancer. Jin Young Kim; Won Young Jang; Mi Hwa Heo; Kang Kuk Lee; Young Rok Do; Keon Uk Park; Hong Suk Song; Yoon Nyun Kim // Cancer Research & Treatment;Sep2012, Vol. 44 Issue 3, p173 

    Purpose The pattern of double primary cancers after treatment for gastric cancer is important for a patient's survival. Materials and Methods We analyzed the clinicopathologic data of 214 gastric cancer patients from October 1996 to November 2007 with regard to metachronous second primary...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics